SCHEMBL392862

SCHEMBL392862

CC(C)(C)N(CC(=O)OCc1ccccc1)C(=O)OCOC(=O)c1ccc(-n2cccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 1/20 0.43
LMNA P02545 1/20 0.41
KMT2A Q03164 3/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
RAB9A P51151 2/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
GPR119 Q8TDV5 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36
JMJD6 Q6NYC1 1/20 0.36
PKM P14618 1/20 0.36
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL394173 0.87 MAPT (0.47) MAPTTDP1L3MBTL1ALDH1A1HPGD
SCHEMBL392819 0.87 MAPT (0.49) MAPTTDP1L3MBTL1ALDH1A1HPGD
SCHEMBL395726 0.87 KMT2A (0.48) MAPTTDP1L3MBTL1ALDH1A1HPGD
SCHEMBL393493 0.86 MAPT (0.45) MAPTTDP1L3MBTL1ALDH1A1HPGD
SCHEMBL395276 0.86 MAPT (0.45) MAPTTDP1L3MBTL1ALDH1A1HPGD
SCHEMBL395232 0.85 MAPT (0.44) MAPTTDP1ALDH1A1HPGDLMNA
SCHEMBL390695 0.84 MAPT (0.44) MAPTTDP1L3MBTL1ALDH1A1HPGD
SCHEMBL393109 0.84 KMT2A (0.44) MAPTTDP1L3MBTL1ALDH1A1HPGD
SCHEMBL393202 0.83 MAPT (0.42) MAPTTDP1L3MBTL1ALDH1A1HPGD
SCHEMBL394304 0.83 KMT2A (0.49) MAPTTDP1ALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP claimed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO claimed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US claimed
US-8101590-B2 9-aminocarbonylsubstituted derivatives of glycylcyclines WYETH LLC (US) 2012-01-24 US disclosed
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP disclosed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO disclosed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines Q6ZSR9, GMPS, RPS10 MAPT 4452/4885TDP1 4661/4885L3MBTL1 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.